The Wegovy UK licence: what it permits, who it covers, and what changed in 2026

The core licence: what Wegovy is and isn't approved for in the UK

The simplest way to frame this decision is to start with what the licence actually permits. Wegovy is licensed in the UK for weight management in adults, used alongside a reduced-calorie diet and increased physical activity. The BMI threshold is 30 or above, or 27 to 29.9 where at least one weight-related condition is also present. Conditions that qualify include type 2 diabetes, high blood pressure, raised cholesterol, and obstructive sleep apnoea, among others.

What the licence does not permit is treating type 2 diabetes. Semaglutide appears in two other UK-licensed brands (Ozempic (injection) and Rybelsus (tablet)) both of which are diabetes medicines. Wegovy is specifically the weight-management brand, and the two uses are not interchangeable. If you have come across references to whether semaglutide is licensed for weight loss and felt confused by which brand does what, that distinction is the core of it.

Wegovy also holds a UK authorisation for reducing major cardiovascular event risk in eligible adults. And from 3 July 2026, a conditional approval was granted for a form of fatty liver disease (MASH). Neither of those indications is relevant to private weight-management prescribing at a service like ours, but they are part of why semaglutide's clinical profile continues to grow.

The 2026 licence expansions that changed what's available

Two approvals in early 2026 meaningfully extended what the Wegovy licence covers.

First, in January 2026, the MHRA approved a 7.2mg maintenance dose of the injectable pen, initially supplied as three 2.4mg pens per week. Then, on 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg pen: one pre-set weekly injection with a built-in covered needle that locks after use. That pen is licensed for adults with a BMI of 30 or above only, the lower 27 threshold does not apply to the 7.2mg format. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide's results. You can read more about the timeline of Wegovy's UK approvals if the history is useful context.

Second, on 11 June 2026, the MHRA approved oral Wegovy tablets. This made the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. The tablet reaches a 25mg maintenance dose through a slow escalation, 1.5mg, then 4mg, then 9mg, each step held for at least a month before moving up. The main practical difference is convenience: no refrigeration, no injections, no sharps disposal. Clinical trial data from the OASIS 4 study showed an average weight loss of around 13.6% over 64 weeks regardless of adherence, rising to roughly 17% among participants who stayed fully on track with treatment. Semaglutide's wider clinical background puts these numbers in context alongside the injection data.

The NICE recommendation and where the NHS licence sits

Having a UK licence and being recommended by NICE are two different things, and it is worth being clear about that distinction. NICE appraised the injectable Wegovy (TA875, published March 2023) and recommended it, but only for use within a specialist weight management service, for a maximum of two years, and for adults with a BMI of 35 or above with at least one weight-related comorbidity. Thresholds are 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

The oral Wegovy tablet does not yet have a NICE appraisal, so it is not currently available on the NHS. Private prescription is the only route for people who want it now.

NHS waiting lists for the injectable form through specialist services are commonly long, and many people find private treatment is the practical option, particularly if their BMI sits below the NICE threshold or they simply cannot afford to wait. If cost is part of the calculation, a fair-minded look at what Wegovy costs privately in the UK is worth reading before assuming the headline price is the full picture. Ordering on a weekday before noon matters for same-day dispatch, something to keep in mind if payday or a Monday start date is part of your planning.

The frequently asked questions page covers some of the practical questions that come up most often about starting treatment privately. For a broader look at how semaglutide is used across its licensed forms, the Wegovy treatment page is a natural next step.

What the licence means for your decision

If your BMI and health picture fall within the licensed criteria, Wegovy is a clinically established option with an evidence base built over several years and two major regulatory approvals. The question of which format suits you (injection or tablet, lower dose or higher) is not one to settle from a webpage. That depends on your health history, any medicines you already take, and how you feel about weekly injections versus a daily tablet routine. A prescriber who reads your full consultation answers is the right person to work through that with you.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not automated software) and if treatment is appropriate, it is dispatched the same day for free next-working-day delivery. You can explore your treatment options and speak to our prescribers when you are ready. The clinical team profile is there if you would like to know more about who would be reviewing your case.

For the evidence behind semaglutide's results, the semaglutide dose sequence page and the NICE appraisal of Wegovy at nice.org.uk/guidance/ta875 are both worth reading. The MHRA's own overview of GLP-1 medicines on GOV.UK gives a clear regulatory picture if you want to go deeper on what the licence means in practice.